Literature DB >> 24120457

Investigations of TB vaccine-induced mucosal protection in mice.

Azra Blazevic1, Christopher S Eickhoff1, Jaime Stanley1, Mark R Buller2, Jill Schriewer2, Eric M Kettelson2, Daniel F Hoft3.   

Abstract

A better understanding of mucosal immunity is required to develop more protective vaccines against Mycobacterium tuberculosis. We developed a murine aerosol challenge model to investigate responses capable of protecting against mucosal infection. Mice received vaccinations intranasally with CpG-adjuvanted antigen 85B (Ag85B/CpG) and/or Bacillus Calmette-Guerin (BCG). Protection against aerosol challenge with a recombinant GFP-expressing BCG was assessed. Mucosal prime/boost vaccinations with Ag85B/CpG and BCG were protective, but did not prevent lung infection indicating more efficacious mucosal vaccines are needed. Our novel finding that protection correlated with increased airway dendritic cells early post-challenge could help guide the development of enhanced mucosal vaccines.
Copyright © 2013 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  BCG; Mucosal specific immunity; Mycobacterium tuberculosis (Mtb); Vaccination

Mesh:

Substances:

Year:  2013        PMID: 24120457      PMCID: PMC3947004          DOI: 10.1016/j.micinf.2013.09.006

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  23 in total

1.  Bacille Calmette-Guérin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype.

Authors:  D F Hoft; R M Brown; S T Roodman
Journal:  J Immunol       Date:  1998-07-15       Impact factor: 5.422

2.  Mucosal bacille calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses.

Authors:  D F Hoft; R M Brown; R B Belshe
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

3.  Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature.

Authors:  T F Brewer
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

4.  A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein.

Authors:  Y Luo; A Szilvasi; X Chen; W C DeWolf; M A O'Donnell
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

5.  Does the efficacy of BCG decline with time since vaccination?

Authors:  J A Sterne; L C Rodrigues; I N Guedes
Journal:  Int J Tuberc Lung Dis       Date:  1998-03       Impact factor: 2.373

6.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.

Authors:  G A Colditz; T F Brewer; C S Berkey; M E Wilson; E Burdick; H V Fineberg; F Mosteller
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

Review 7.  Mouse models for studying orthopoxvirus respiratory infections.

Authors:  Jill Schriewer; R Mark L Buller; Gelita Owens
Journal:  Methods Mol Biol       Date:  2004

8.  Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi.

Authors:  S Langermann; S Palaszynski; A Sadziene; C K Stover; S Koenig
Journal:  Nature       Date:  1994-12-08       Impact factor: 49.962

9.  Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.

Authors:  Samuel J McConkey; William H H Reece; Vasee S Moorthy; Daniel Webster; Susanna Dunachie; Geoff Butcher; Jenni M Vuola; Tom J Blanchard; Philip Gothard; Kate Watkins; Carolyn M Hannan; Simone Everaere; Karen Brown; Kent E Kester; James Cummings; Jackie Williams; D Gray Heppner; Ansar Pathan; Katie Flanagan; Nirmalan Arulanantham; Mark T M Roberts; Michael Roy; Geoffrey L Smith; Joerg Schneider; Tim Peto; Robert E Sinden; Sarah C Gilbert; Adrian V S Hill
Journal:  Nat Med       Date:  2003-05-25       Impact factor: 53.440

10.  Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.

Authors:  Jenni M Vuola; Sheila Keating; Daniel P Webster; Tamara Berthoud; Susanna Dunachie; Sarah C Gilbert; Adrian V S Hill
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

View more
  4 in total

1.  Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not?

Authors:  Renata Monteiro-Maia; Rosa Teixeira de Pinho
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-09       Impact factor: 2.743

2.  Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization.

Authors:  Aneesh Thakur; Cristina Rodríguez-Rodríguez; Katayoun Saatchi; Fabrice Rose; Tullio Esposito; Zeynab Nosrati; Peter Andersen; Dennis Christensen; Urs O Häfeli; Camilla Foged
Journal:  Front Immunol       Date:  2018-11-30       Impact factor: 7.561

3.  BCG Vaccination Induces M. avium and M. abscessus Cross-Protective Immunity.

Authors:  Getahun Abate; Fahreta Hamzabegovic; Christopher S Eickhoff; Daniel F Hoft
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

4.  Repeated Aerosolized-Boosting with Gamma-Irradiated Mycobacterium bovis BCG Confers Improved Pulmonary Protection against the Hypervirulent Mycobacterium tuberculosis Strain HN878 in Mice.

Authors:  Seung Bin Cha; Woo Sik Kim; Jong-Seok Kim; Hongmin Kim; Kee Woong Kwon; Seung Jung Han; Seok-Yong Eum; Sang-Nae Cho; Sung Jae Shin
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.